Details for Patent: 10,835,517
✉ Email this page to a colleague
Which drugs does patent 10,835,517 protect, and when does it expire?
Patent 10,835,517 protects XDEMVY and is included in one NDA.
This patent has sixteen patent family members in thirteen countries.
Drugs Protected by US Patent 10,835,517
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus | XDEMVY | lotilaner | SOLUTION/DROPS;OPHTHALMIC | 217603-001 | Jul 24, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF DEMODEX BLEPHARITIS VIA TOPICAL ADMINISTRATION TO AN OCULAR SURFACE | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,835,517
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018385766 | ⤷ Subscribe | |||
| Australia | 2023200843 | ⤷ Subscribe | |||
| Brazil | 112020012018 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
